ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bulevirtide

Also written as “Bulevirtide” and “Bulevirtide (BLV)”.

Its studies are mostly in Hepatitis D, Chronic, led by 2 companies.

Drug pageBulevirtide: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 21, 20195 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciencesits history only40 open or runningphase 3since Feb 21, 2019Feb 21, 2019none ahead
Mirum Pharmaceuticals11 open or runningphase 3since Mar 2, 2026Mar 2, 2026Aug 31, 2027phase 3 · NCT07454837

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Mirum Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named bulevirtideINNProposed as its International Nonproprietary Name in WHO's List 118
  2. Mar 2, 2026First study: phase 3 study in Hepatitis D, ChronicFirst studyNCT07454837 · 120 planned · Austria, Czechia, France and more

Ahead

  1. Aug 31, 2027Primary completion: phase 3 study in Hepatitis D, ChronicNCT07454837

TargetBeta

SLC10A1 →read by rule
“Bile acid transporter inhibitor”ChEMBL 37, by rule

Other programs on SLC10A1

ProgramCompanyFurthest phaseStudies
hepalatideruleshanghai-hep-pharmaceutical-co-ltdphase 38

Studies

The one study Mirum Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07454837Hepatitis D, Chronic · Austria, Czechia, France and more3RecruitingAug 31, 2027120

How it is read

Names in the registry

  • “Bulevirtide”, 5 entries
  • “Bulevirtide (BLV)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.